CRM vs PANW: Which Is the Better Buy?

Side-by-side comparison of Salesforce, Inc. and Palo Alto Networks, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-22.
Salesforce, Inc. · Technology
$182.14
+200.4% upside to fair value
Grade B High Quality
VS
Palo Alto Networks, Inc. · Technology
$174.96
+15.2% upside to fair value
Grade B High Quality
QuantHub Verdict
CRM has more upside to fair value (+200.4%). CRM trades at a lower forward P/E (22.8x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric CRM PANW
Current Price $182.14 $174.96
Fair Value Estimate $547.17 $201.61
Upside to Fair Value +200.4% +15.2%
Market Cap $173.0B $119.2B
Forward P/E 22.8x 94.9x
EV / EBITDA 14.4x 52.4x
Price / Sales 4.2x 12.1x
Price / FCF 12.0x 29.3x
Revenue Growth YoY +12.1% +14.9%
Gross Margin 77.7% 73.5%
Operating Margin 21.5% 14.4%
Return on Equity 12.4% 15.5%
Dividend Yield 0% 0%
FCF Yield 8.33% 3.41%
Analyst Consensus Buy Strong Buy
Investment Thesis
CRM — Salesforce, Inc.
Salesforce, Inc. is a leading enterprise software company specializing in cloud-based customer relationship management and enterprise applications. The company benefits from a durable competitive moat anchored by pioneering SaaS delivery, a large and growing customer base, and a diversified revenue mix with Service Cloud as the largest segment generating $9.05 billion in FY2025. Salesforce exhibi…
PANW — Palo Alto Networks, Inc.
Palo Alto Networks is a leading cybersecurity company specializing in AI-driven cloud security platforms, subscription services, and hardware products. The company benefits from a durable competitive moat driven by its platform transformation under CEO Nikesh Arora, with over 50% of revenue from high-margin subscription services growing at 25.6% year-over-year in fiscal 2024. Despite a premium va…
Accumulation Zones
Metric CRM PANW
Zone Low $410.38 $151.21
Zone High $465.09 $171.37
In Buy Zone? Yes No
← CRM Research    PANW Research →    All Research